Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) as Induction Therapy and a Randomized Trial of Thalidomide vs Thalidomide Plus Oral Idarubicin as Maintenance Therapy in Patients With Multiple Myeloma
Background: In some studies, thalidomide in combination with chemotherapy has been shown to
be effective in patients with relapsed or refractory multiple myeloma (MM). In this study,
the researchers have chosen a regimen which can be administered on an outpatient basis.
After 3-8 cycles of T-CID patients with at least stable disease will be randomized to
receive thalidomide or thalidomide plus oral idarubicin as maintenance therapy for at least
one year or until progression.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Induction therapy: response rate, overall survival, death rate
Ingo Schmidt-Wolf, MD
University Hospital, Bonn
Germany: Federal Institute for Drugs and Medical Devices